Human granulocyte CD11b expression as a pharmacodynamic biomarker of inflammation

Journal of Immunological Methods

Volumn 240, Issue 1-2, 2000, Pages 125-132

  Davis, Hugh M ^a   Carpenter, Donald C ^b   Stahl, Jocelyn M ^a   Zhang, Wenyu ^a   Hynicka, Weslia P ^a   Griswold, Don E ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Pulmonary Pharmacology Department   (United States)

Author keywords

CD11b; Flow cytometry; Granulocyte; Inflammation

Indexed keywords

CD11B ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ACRYLATES; ADJUVANTS, IMMUNOLOGIC; BINDING, COMPETITIVE; FLOW CYTOMETRY; HUMANS; INFLAMMATION; INTEGRINS; LEUKOTRIENE B4; LEUKOTRIENE D4; LIPOPOLYSACCHARIDES; MACROPHAGE-1 ANTIGEN; MALE; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PYRIDINES; RECEPTORS, LEUKOTRIENE B4;

EID: 0034705657     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00183-6     Document Type: Article

References (34)

1. Allen R.C., Stevens D.L. The circulating phagocyte reflects the in vivo state of immune defense. Curr. Opin. Infect Dis. 5:1992;389.
2. Bohn B. High-sensitivity cytofluorometric quantitation of lectin and hormone binding to surfaces of living cells. Exp. Cell Res. 103:1976;39.
3. Busse W.W. Leukotrienes and inflammation. Am. J. Respir. Crit. Care Med. 157:1998;S210. discussion S247.
4. Colburn W.A. Selecting and validating biologic markers for drug development. J. Clin. Pharmacol. 37:1997;355.
5. Daines R.A., Chambers P.A., Pendrak I., Jakas D.R., Sarau H.M., Foley J.J., et al. Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships. J. Med. Chem. 36:1993;3321.
6. Fearon D.T., Collins L.A. Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. J. Immunol. 130:1983;370.
7. Gao J.X., Issekutz A.C. Mac-1 (CD11b/CD18) is the predominant beta 2 (CD18) integrin mediating human neutrophil migration through synovial and dermal fibroblast barriers. Immunology. 88:1996;463.
8. Hickstein D.D., Ozols J., Williams S.A., Baenziger J.U., Locksley R.M., Roth G.J. Isolation and characterization of the receptor on human neutrophils that mediates cellular adherence. J. Biol. Chem. 262:1987;5576.
9. Kim J., Logothetis C.J. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol. Clin. North Am. 26:1999;281.
10. Kuhns D.B., Alvord W.G., Gallin J.I. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J. Infect Dis. 171:1995;145.
11. Luscinskas F.W., Brock A.F., Arnaout M.A., Gimbrone M.A. Jr. Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. J. Immunol. 142:1989;2257.
12. Lynn W.A., Raetz C.R., Qureshi N., Golenbock D.T. Lipopolysaccharide-induced stimulation of CD11b/CD18 expression on neutrophils. Evidence of specific receptor-based response and inhibition by lipid A-based antagonists. J. Immunol. 147:1991;3072.
13. Marder P., Schultz R.M., Spaethe S.M., Sofia M.J., Herron D.K. Flow cytometric evaluation of the effects of leukotriene B4 receptor antagonists (LY255283 and SC-41930) on calcium mobilization and integrin expression of activated human neutrophils. Prostaglandins Leukotrienes Essent Fatty Acids. 46:1992;265.
14. Marder P., Sawyer J.S., Froelich L.L., Mann L.L., Spaethe S.M. Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4- (4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist. Biochem. Pharmacol. 49:1995;1683.
15. Matsukawa A., Yoshinaga M. Neutrophils as a source of cytokines in inflammation. Histol. Histopathol. 14:1999;511.
16. McCarthy D.A., Macey M.G. A simple flow cytometric procedure for the determination of surface antigens on unfixed leucocytes in whole blood. J. Immunol. Methods. 163:1993;155.
17. Miotla J.M., Williams T.J., Hellewell P.G., Jeffery P.K. A role for the beta2 integrin CD11b in mediating experimental lung injury in mice. Am. J. Respir. Cell Mol. Biol. 14:1996;363.
18. Nogare A.R., Yarbrough W.C. Jr. A comparison of the effects of intact and deacylated lipopolysaccharide on human polymorphonuclear leukocytes. J. Immunol. 144:1990;1404.
19. Nussler A.K., Wittel U.A., Nussler N.C., Beger H.G. Leukocytes, the Janus cells in inflammatory disease. Langenbecks Arch. Surg. 384:1999;222.
20. Parkos C.A. Molecular events in neutrophil transepithelial migration. Bioessays. 19:1997;865.
21. Price T.H., Beatty P.G., Corpuz S.R. In vivo inhibition of neutrophil function in the rabbit using monoclonal antibody to CD18. J. Immunol. 139:1987;4174.
22. Repo H., Jansson S.E., Leirisalo-Repo M. Flow cytometric determination of CD11b upregulation in vivo. J. Immunol. Methods. 164:1993;193.
23. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 220:1983;568.
24. Sarau H.M., Foley J.J., Schmidt D.B., Tzimas M.N., Martin L.D., Daines R.A., et al. SB 209247, a high affinity LTB4 receptor antagonist demonstrating potent antiinflammatory activity. Adv. Prostaglandin Thromboxane Leukotriene Res. 23:1995;275.
25. Schultz R.M., Marder P., Spaethe S.M., Herron D.K., Sofia M.J. Effects of two leukotriene B4 (LTB4) receptor antagonists (LY255283 and SC-41930) on LTB4-induced human neutrophil adhesion and superoxide production. Prostaglandins Leukotriene Essent. Fatty Acids. 43:1991;267.
26. Showell H.J., Pettipher E.R., Cheng J.B., Breslow R., Conklyn M.J., Farrell C.A., et al. The in vitro and in vivo pharmacologic activity of the potent and selective leukotriene B4 receptor antagonist CP-105696. J. Pharmacol. Exp. Ther. 273:1995;176.
27. Showell H.J., Conklyn J.J., Alpert R., Hingorani G.P., Wright K.F., Smith M.A., et al. The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543. J. Pharmacol. Exp. Ther. 285:1998;946.
28. Simon S.I., Chambers J.D., Sklar L.A. Flow cytometric analysis and modeling of cell-cell adhesive interactions: the neutrophil as a model. J. Cell Biol. 111:1990;2747.
29. Sucic M., Kolevska T., Kopjar B., Kosanovic M., Drobnjak M., Zalud I., et al. Accuracy of routine flow-cytometric bitmap selection for three leukocyte populations. Cytometry. 10:1989;442.
30. Terstappen L.W., Shah V.O., Conrad M.P., Recktenwald D., Loken M.R. Discriminating between damaged and intact cells in fixed flow cytometric samples. Cytometry. 9:1988;477.
31. Turner C.R., Breslow R., Conklyn J.J., Andresen C.J., Patterson D.K., Lopez-Anaya A., et al. In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. J. Clin. Invest. 97:1996;381.
32. van der Poll T., Coyle S.M., Levi M., Jansen P.M., Dentener M., Barbosa K., et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 89:1997;3727.
33. Wright S.D., Ramos R.A., Hermanowski-Vosatka A., Rockwell P., Detmers P.A. Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14. J. Exp. Med. 173:1991;1281.
34. Yee K.M., Struthers A.D. Can drug effects on mortality in heart failure be predicted by any surrogate measure? Eur. Heart J. 18:1997;1860.